Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Market Closed - Bombay S.E. 06:00:46 2024-04-16 am EDT 5-day change 1st Jan Change
2,325 INR +0.29% Intraday chart for Dr. Lal PathLabs Limited +1.41% -9.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dr Lal Pathlabs Names CEO MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024 CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates MT
Dr. Lal PathLabs Seeks M&A CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24 CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024 MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002 MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5% MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023 CI
Dr. Lal PathLabs Limited Announces Change in Directorate CI
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835 MT
Dr. Lal PathLabs Seeks Inorganic Opportunity CI
Transcript : Dr. Lal PathLabs Limited, Q1 2024 Earnings Call, Jul 27, 2023
Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24 CI
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Dr. Lal PathLabs Limited acquired additional 10% stake in Aprl Pathlabs Private Limited. CI
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR1,835 From INR1,864, Keeps at Neutral MT
Chart Dr. Lal PathLabs Limited
More charts
Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
2,320 INR
Average target price
2,459 INR
Spread / Average Target
+5.97%
Consensus
  1. Stock Market
  2. Equities
  3. LALPATHLAB Stock
  4. LALPATHLAB Stock
  5. News Dr. Lal PathLabs Limited
  6. Dr. Lal PathLabs' Consolidated Profit Climbs in Fiscal Q2 But Misses Estimates